Table 4.

Effects of apoB-depleted serum, HDL, HDL-associated apolipoproteins and lipids or mimetic peptides on eosinophil function in human studies utilizing primary eosinophils and in studies utilizing animal models.

ApoB-Depleted Serum, HDL, HDL-Associated Protein/Lipid, Mimetic Peptide	Human Study/Animal Model	Effect on Eosinophils	References
Human studies
apoB-depleted serum, HDL	Allergic rhinitis patients, human eosinophils	Inhibited shape change and chemotaxis	[28]
HDL	Atopic dermatitis patients, human eosinophils	Decreased ability to inhibit shape change and chemotaxis	[34]
HDL, apoA-I, apoA-IV	Allergic patients, human eosinophils	Decreased chemotaxis, accelerated apoptosis	[29]
Stable LPC analog Miltefosine	Human eosinophils	Inhibited shape change, CD11b expression, chemotaxis, degranulation, CD63 expression and Ca2+ flux	[253]
Animal studies
apoA-I, apoA-IV, 5A-peptide	House dust mite-induced asthma mouse model	Decreased bronchoalveolar lavage fluid eosinophils	[29,31,228]
D-4F	OVA-challenged mouse model	Decreased airway eosinophilia	[255]
LPC 18:0	Allergic cell recruitment mouse model	Decreased infiltration into the lungs	[72]
Stable LPC analog Miltefosine	Allergic cell recruitment; allergic lung inflammation mouse models	Suppressed eosinophil migration into the bronchoalveolar lavage; reduced eosinophil numbers, improved lung resistance	[253]

A summary of the effects of apoB-depleted serum, HDL, HDL-associated apolipoproteins and lipids, as well as apoA-I mimetic peptides on eosinophil activation and functional properties is given, as described from human studies utilizing primary eosinophils or studies utilizing animal models. Abbreviations: apoA-I—apolipoprotein A-I; apoA-IV—apolipoprotein A-IV; apoB—apolipoprotein B; CD—cluster of differentiation; HDL—high-density lipoprotein; LPC—lysophosphatidylcholine; OVA—ovalbumin.